GlassScriptPhysician profile
Michael Joseph Warren
NPI 1568963551
$7,039.61
in general payments reported to CMS, 2019-2025
30 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.08 · 2021: $351 · 2022: $884 · 2023: $1,201 · 2024: $2,305 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,444 · Travel and Lodging: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,443.77 |
| Travel and Lodging | $332.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,369.18 | 2021-2025 | Rinvoq, Skyrizi, Mavyret |
| Boston Scientific Corporation | $596.24 | 2022-2024 | Spyglass, Hydratome Rx 44, Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.35 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Pfizer INC. | $389.52 | 2024-2025 | |
| Janssen Biotech, INC. | $329.57 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $218.05 | 2021-2025 | Epclusa |
| Qol Medical, LLC | $179.59 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $159.09 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Apollo Endosurgery US INC | $155.57 | 2023 | Overstitch Endoscopic Suturing System |
| Ferring Pharmaceuticals INC. | $154.02 | 2023-2024 | Rebyota |
| Genzyme Corporation | $141.51 | 2024-2025 | |
| Madrigal Pharmaceuticals | $134.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $125.84 | 2024 | Nexpowder |
| Janssen Scientific Affairs, LLC | $107.88 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $80.84 | 2024-2025 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $77.87 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $59.41 | 2024-2025 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $38.48 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $31.06 | 2025 | Voquezna |
| Biocon Biologics INC | $28.77 | 2025 | Yesintek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.08 | 2020 | |
| Aimmune Therapeutics, INC. | $25.66 | 2024 | |
| La Jolla Pharmaceutical Company | $22.99 | 2021 | |
| Lilly USA, LLC | $21.50 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $18.53 | 2021 | |
| Ardelyx, INC. | $15.11 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $13.19 | 2022 | |
| Daiichi Sankyo INC. | $13.15 | 2024 | Injectafer |
| Almatica Pharma LLC | $11.39 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $10.13 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.